SKLB1002

SKU: orb1305507

Description

SKLB1002 is a potent, ATP-competitive small molecule inhibitor targeting VEGFR2 with an IC50 of 32 nM. It is widely used in biochemical and cellular assays to study angiogenesis and has demonstrated efficacy in inhibiting tumor growth in various preclinical cancer models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1225451-84-2
• MW: 320.39
• Purity: >99.99% (May vary between batches)
• Formula: C₁₃H₁₂N₄O₂S₂
• SMILES: CC1=NN=C(SC2=C3C=C(OC)C(OC)=CC3=NC=N2)S1
• Target: VEGFR
• Solubility: DMSO:1 mg/mL (3.12 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  VEGFR2:32 nM
• In Vivo:
  SKLB1002 significantly inhibited human umbilical vein endothelial cell proliferation, migration, invasion, and lumen formation by inhibiting VEGF-induced phosphorylation of VEGFR2 kinase and downstream protein kinases, including ERK, FAK, and Src.SKLB1002 significantly reduced cytotoxicity of L-02 in normal human cells.
  Read more...
• In Vitro:
  SKLB1002 significantly inhibited human umbilical vein endothelial cell proliferation, migration, invasion, and lumen formation by inhibiting VEGF-induced phosphorylation of VEGFR2 kinase and downstream protein kinases, including ERK, FAK, and Src.SKLB1002 significantly reduced cytotoxicity of L-02 in normal human cells.
  Read more...
• Cell Research:
  Cell proliferation is measured using MTT assay. Various cells including HUVECs, L-02, B16-F10, HepG2, and SW620 are treated with indicated concentrations of SKLB1002 for 24 hours. Vandetanib and sunitinib serve as positive controls. Each assay is replicated 3 times.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SKLB 1002, SKLB1002, SKLB-1002, VEGFR2

Compound Identifiers

PubChem CID

71461003